Get informed when a big investor buys or sells
+ Follow90.84%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Bioxytran (BIXT) currently reports a ROE of 90.84%. That is above the Healthcare sector average of 13.1%. Use the charts on this page to explore Bioxytran's ROE history and peer comparisons.
Bioxytran's ROE of 90.84% is higher than the Healthcare sector average of 13.1%. That is roughly 593.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Bioxytran's current 90.84% should be judged against Healthcare norms (sector average: 13.1%) and against BIXT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 90.84%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Bioxytran, and consider following BIXT for alerts when major investors trade the stock.
Bioxytran is classified in the Healthcare sector. On ROE, it currently shows 90.84% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BIXT with unrelated industries.